Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Immunohistochemistry screening for TP53 mutation in myeloid neoplasms in AZF-fixed bone marrow biopsies.

Pathology - 1 Apr 2024

Yang Guang, Anderson Williams Sarah, He Fiona, He Yuyu, McIntyre Kelsey, Beckman Amy K, Nelson Andrew C, Yohe Sophia L

Abstract excerpt

TP53 mutational status in myeloid neoplasms is prognostic and in acute myeloid leukaemia (AML) may lead to alternative induction therapy; therefore, rapid assessment is necessary for precision treatment. Assessment of multiple prognostic genes by next generation sequencing in AML is standard of care, but the turn-around time often cannot support rapid clinical decision making. Studies in haematological neoplasms...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biopsy
Share to Bone Marrow
Share to Immunohistochemistry

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Leukemia, Myeloid, Acute

Share to Mutation

Share to Myeloproliferative Disorders

Share to Tumor Suppressor Protein p53

Source

Identifiers

PMID: 38341302
DOI: 10.1016/j.pathol.2023.11.009

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Immunohistochemistry screening for TP53 mutation in myeloid neoplasms in AZF-fixed bone marrow biopsies.PMID 38341302Read ↗

Detection of TP53 mutations by immunohistochemistry in acute myeloid leukemia varies with interpreter expertise and mutation status.Semantic proximity Read ↗

A clinical guide to TP53 mutations in myeloid neoplasms.Semantic proximity Read ↗

TP53 mutations in myeloid neoplasms: implications for accurate laboratory detection, diagnosis, and treatment.Semantic proximity Read ↗

Correlation of p53 immunohistochemistry with TP53 mutational status and overall survival in newly diagnosed acute myeloid leukaemia.Semantic proximity Read ↗

Early identification of TP53 mutations and TP53 allelic state in myelodysplastic neoplasms and acute myeloid leukemia via point‐of‐care p53 immunohistochemistrySemantic proximity Read ↗

TP53 copy number and protein expression inform mutation status across risk categories in acute myeloid leukemia.Semantic proximity Read ↗

Utility of p53 immunohistochemistry as a surrogate for sequencing in myeloid neoplasms: A tale of caution.Semantic proximity Read ↗

p53 immunohistochemistry as an ancillary tool for rapid assessment of residual disease in TP53-mutated acute myeloid leukemia and myelodysplastic syndromes.Semantic proximity Read ↗

Immunohistochemistry for p53 is a useful tool to identify cases of acute myeloid leukemia with myelodysplasia-related changes that are TP53 mutated, have complex karyotype, and have poor prognosis.Semantic proximity Read ↗

Exploring p53 protein expression and its link to TP53 mutation in myelodysplasia-related malignancies-Interpretive challenges and potential field of applications.Semantic proximity Read ↗

TP53 Amplification, a Rare but Recurrent Alteration in Myeloid Neoplasms.Semantic proximity Read ↗

Correlation of NPM1 immunohistochemistry with mutation subtypes, clinicopathologic variables and molecular testing in AML with NPM1 mutation.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.